" class="no-js "lang="en-US"> Swissmedic Authorizes Moderna’s Omicron-targeting Bivalent Booster Candidate, mRNA-1273.214 - Medtech Alert
Friday, February 03, 2023

Swissmedic Authorizes Moderna’s Omicron-targeting Bivalent Booster Candidate, mRNA-1273.214

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic has granted temporary authorization for the use of Moderna’s Omicron-targeting bivalent booster vaccine, Spikevax Bivalent Original/Omicron (mRNA-1273.214) for active immunization to prevent SARS-CoV-2 virus-induced Coronavirus-2019 disease for individuals aged 18 years and older. Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains 25 µg of mRNA-1273 (Spikevax) and 25 µg of a vaccine candidate targeting the Omicron variant of concern (BA.1).

“We are delighted to receive authorization from Swissmedic for our next-generation bivalent vaccine, mRNA-1273.214. This is another example of Switzerland’s continued leadership in helping to end the COVID-19 pandemic,” said Arpa Garay, Chief Commercial Officer at Moderna. “Moderna is proud to play a key role in helping to protect the people of Switzerland from the ongoing threat that COVID-19 represents to global public health.”

The decision from Swissmedic is based on clinical trial data from a Phase 2/3 trial, in which mRNA-1273.214 met all primary endpoints, including superior neutralizing antibody response against Omicron (BA.1) when compared to the currently authorized 50 µg booster dose of Spikevax (mRNA-1273) in previously uninfected participants. A booster dose of Spikevax Bivalent Original/Omicron (mRNA-1273.214) increased neutralizing geometric mean titers (GMT) against Omicron approximately 8-fold above baseline levels. In addition, Spikevax Bivalent Original/Omicron (mRNA-1273.214) elicited higher neutralizing antibody titers against the Omicron subvariants BA.4 and BA.5 when compared to Spikevax (mRNA-1273) regardless of prior infection status or age, including in those aged 65 and older. mRNA-1273.214 was generally well tolerated, with a reactogenicity and safety profile consistent with the currently authorized booster.

Moderna is working with Swissmedic and the Government of Switzerland to make Spikevax Bivalent Original/Omicron available to people in Switzerland, with the aim of supplying product in early September. Moderna has received approval for mRNA-1273.214 in the UK and has completed regulatory submissions for the next-generation vaccine worldwide.

People In This Post

Companies In This Post

  1. Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer Read more
  2. Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials Read more
  3. Trelleborg to Expand its BioPharmaceutical Manufacturing Footprint in Europe Read more
  4. Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch Read more
  5. Accenture Expands Strategy Capabilities in Life Sciences with the Acquisition of Bionest Read more